Quick Answer
Cytek Biosciences, Inc. reported Operating Income of -$40.38 million for fiscal year 2025.
Cytek Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$40.38M | -96.8% |
| 2024 | -$20.52M | +26.3% |
| 2023 | -$27.84M | -1443.5% |
| 2022 | -$1.80M | -119.7% |
| 2021 | $9.16M | -33.0% |
| 2020 | $13.66M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$9.19M | -116.4% | +13.5% |
| June 30, 2025 | -$10.62M | -24.6% | +29.1% |
| March 31, 2025 | -$14.97M | -39.5% | -252.5% |
| September 30, 2024 | -$4.25M | +33.8% | +50.2% |
| June 30, 2024 | -$8.53M | +6.6% | +20.6% |
| March 31, 2024 | -$10.73M | +11.7% | -67.2% |
| September 30, 2023 | -$6.42M | -572.1% | +29.7% |
| June 30, 2023 | -$9.13M | -924.4% | +25.0% |
- Cytek Biosciences, Inc. showed a decrease of -96.8% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Cytek Biosciences, Inc.’s operating income has declined by 395.7% (from $13.66 million to -$40.38 million).
- The most recent figure is from Cytek Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: